Telomere length analysis provides unique insights into the pathogenesis of MDS and AML and is associated with a worse overall survival in MDS but not AML

被引：0
|
作者：
Williams, J. [1 ]
Knapper, S. [1 ]
Hills, R. [1 ]
Pepper, C. [1 ]
Fegan, C. [1 ]
Baird, D. [1 ]
机构：
[1] Sch Med, Inst Canc & Genet, CLL Res Grp, Cardiff, S Glam, Wales
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2015年 / 169卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
217
引用
收藏
页码：88 / 88
页数：1
相关论文
共 50 条
  • [31] Pre-transplant cytoreductive therapy can improve overall survival of patients with MDS-AML but not MDS-EB2 receiving HLA-matched sibling donor peripheral blood stem cell transplantation
    Wang, Qianqian
    Zhao, Xingli
    Liu, Zixian
    Zhao, Xiaoli
    Zhang, Guixin
    Yao, Jianfeng
    Zheng, Xiaohui
    Zhang, Lining
    Shen, Yuyan
    He, Yi
    Huang, Yong
    Zhang, Rongli
    Wei, Jialin
    Ma, Qiaoling
    Pang, Aiming
    Yang, Donglin
    Jiang, Erlie
    Feng, Sizhou
    Zhang, Zhuoran
    Zhai, Weihua
    Han, Mingzhe
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (04): : 1218 - 1228
  • [32] Bone Marrow Fibrosis Assessed by Computer-Assisted Image Analysis (CIA) is Associated with Poor Risk Cytogenetics and Lower Overall Survival after Allogeneic HSCT for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
    Mohamed, Said Yousuf
    Bakshi, Nasir A.
    Salama, Mohamed E.
    Al Humaid, Saleh
    Al Ghasham, Nahlah
    Hassanein, Mona
    Al Mohareb, Fahad
    Aljurf, Mahmoud D.
    Al Zahrani, Hazzaa
    Elhassan, Tusneem A.
    Ghobashi, Emad
    Alfraih, Feras
    Hussain, Fazal
    Ahmed, Syed O.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S229 - S230
  • [33] Modifier genetics in zebrafish identify Chk1 and an associated survival pathway as targets for pharmacotherapy of MDS/AML with P53 mutations.
    Sidi, Samuel
    Hagen, Andreas T.
    Kennedy, Richard
    Imamura, Shintaro
    Kishi, Shuji
    Kanki, John
    D'Andrea, Alan
    Look, A. Thomas
    BLOOD, 2006, 108 (11) : 416A - 416A
  • [34] Cytogenetic Clonal Evolution in MDS Is Associated with Shifts towards Unfavorable Karyotypes According to IPSS and Shorter Overall Survival: A Study on 988 MDS Patients Studied Sequentially by Chromosome Banding Analysis
    Haferlach, Claudia
    Zenger, Melanie
    Alpermann, Tamara
    Schnittger, Susanne
    Kern, Wolfgang
    Haferlach, Torsten
    BLOOD, 2011, 118 (21) : 442 - 443
  • [35] The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
    A Stengel
    W Kern
    T Haferlach
    M Meggendorfer
    A Fasan
    C Haferlach
    Leukemia, 2017, 31 : 705 - 711
  • [36] The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
    Stengel, A.
    Kern, W.
    Haferlach, T.
    Meggendorfer, M.
    Fasan, A.
    Haferlach, C.
    LEUKEMIA, 2017, 31 (03) : 705 - 711
  • [37] Retrospective analysis of prognostic factors associated with response and overall survival in patients with RAEB-t MDS treated with decitabine.
    Malik, A.
    Garcia-Manero, G.
    Welch, M.
    Kantarjian, H.
    Stein, K.
    Teng, A.
    Jabbour, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] Impact of Transformation to Acute Myeloid Leukemia (AML) on Overall Survival (OS) among Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) in the United States of America (USA)
    Kota, Vamsi
    Ogbonnaya, Augustina
    Farrelly, Eileen
    Schroader, Bridgette
    Kristo, Fjoralba
    Raju, Aditya
    Dalal, Mehul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S348 - S348
  • [39] Poor-risk AML/MDS patients have improved overall survival after URD alloTX using PBSC compared to BM after busulphan/TBI containing conditioning regimen
    Bertz, H
    Egger, M
    Spyridonidis, A
    Engelhardt, M
    Finke, J
    BONE MARROW TRANSPLANTATION, 2005, 35 : S90 - S90
  • [40] Immune reconstitution at 12 months can predict superior overall survival in reduced intensity alemtuzumab based conditioning transplant recipients for high risk MDS and AML; a single centre experience
    Kanellopoulos, A.
    Saeed, M.
    Kaparou, M.
    Eden, D.
    Khawaja, J.
    Cain, L.
    Qureshi, I.
    Xenou, E.
    Lee, S.
    Randall, K.
    Arbuthnot, C.
    Borg, A.
    Holder, K.
    Bratby, L.
    Kishore, B.
    Lovell, R.
    Paneesha, S.
    Nikolousis, E.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S242 - S242
12345